Matt Henriksen

And I think what you just said explains that it's moving on beyond just glucose, and there's more to it than just glucose.

Yeah.

And Jake, thank you so much for joining us today.

I appreciate you coming in.

And thank you to our producer, Miriam Traore, for all the behind the scenes work.

And thank you to our listeners for tuning in today.

We hope you join us for future episodes.

And if you'd like to stay up to date, you can click the subscribe button on Spotify or your favorite streaming platform.

Take care.

Welcome to another episode of the Vanguards of Healthcare series.

My name is Matt Henriksen, the Medical Technology Analyst at Bloomberg Intelligence, which is the in-house equity research platform of Bloomberg LP.

We are pleased to have with us today Sean Saint, CEO of Beta Bionics, a medical device company that is a key leader in the expansion of automated insulin delivery systems, or AIDs for short, the next generation of insulin pumps to help diabetic patients keep track of their glucose levels.

You can dive deeper into the financials by typing in BBNX Equity Go on your Bloomberg terminal.

Sean, thank you for joining us today.

Thanks for having us, Matt.

And Sean, you know, you started the role of Beta Bionic CEO a few years ago, but what

You've had a long history in the diabetes space, at a personal level as well.

So why don't we start with, for the listeners, a story of your path that got you to the CEO role today?

Yeah, quite a career.

And what caught my attention is you were diagnosed with, I mean, was this type one or type two diabetes you were diagnosed in your adult years?